Cariprazine 1.5–3 mg/d n = 170 | Cariprazine 4.5–6 mg/d n = 361 | Cariprazine 9 mg/d n = 148 | Cariprazine Overall N = 679 | |
---|---|---|---|---|
Completed, n (%) | 70 (41.2) | 154 (42.7) | 48 (32.4) | 272 (40.1) |
Reasons for discontinuation, n (%) | ||||
Adverse event | 28 (16.5) | 29 (8.0) | 26 (17.6) | 83 (12.2) |
Insufficient therapeutic response | 1 (0.6) | 11 (3.0) | 13 (8.8) | 25 (3.7) |
Protocol violation | 13 (7.6) | 31 (8.6) | 10 (6.8) | 54 (8.0) |
Withdrawal of consent | 44 (25.9) | 88 (24.4) | 38 (25.7) | 170 (25.0) |
Lost to follow-up | 11 (6.5) | 29 (8.0) | 10 (6.8) | 50 (7.4) |
Other reasons | 3 (1.8) | 19 (5.3) | 3 (2.0) | 25 (3.7) |
Entered safety follow-up, (n)% | 121 (71.2) | 234 (64.8) | 102 (68.9) | 457 (67.3) |